Movement disorders in adults with intellectual disability and behavioral problems associated with use of antipsychotics
Files
Publication date
2016-08-01
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
Abstract
Background Antipsychotic drugs are prescribed to approximately 30% to 40% of adults with intellectual disability (ID) and behavioral problems despite lack of evidence of effectiveness and potential adverse effects, including movement disorders. Aims The aim of this study was to examine the prevalence of movement disorders (dyskinesia, akathisia, dystonia, and parkinsonism) in in-patient adults with mild to borderline ID and behavioral problems associated with use of antipsychotics. Methods Prevalence of movement disorders was measured with a standardized protocol. The strength of the association between antipsychotic drug use and movement disorders was assessed using logistic regression analysis. Results Almost half (44.0%) of 134 in-patient adults with ID and behavioral problems had any movement disorder. Parkinsonism, dyskinesia, akathisia, and dystonia were present in, respectively, 36.6%, 11.2%, 9.0%, and 0.7% of patients with ID. It appeared that current use of any antipsychotic drug (odds ratio, 3.0; 95% confidence interval, 1.0-8.4) and a dose in target range (odds ratio, 5.5; 95% confidence interval, 1.5-20.4) were significantly associated with the risk of having movement disorders. Conclusions The prevalence of movement disorders in people with ID and behavioral problems is high, especially in ID patients using antipsychotics. More attention is needed for these movement disorders and their potential impact.
Keywords
antipsychotics, intellectual disability, movement disorders, Psychiatry and Mental health, Pharmacology (medical), Journal Article
Citation
Scheifes, A, Walraven, S, Stolker, J J, Nijman, H L I, Tenback, D E, Egberts, T C G & Heerdink, E R 2016, 'Movement disorders in adults with intellectual disability and behavioral problems associated with use of antipsychotics', Journal of Clinical Psychopharmacology, vol. 36, no. 4, pp. 308-313. https://doi.org/10.1097/JCP.0000000000000528